Francisco Corpi
Latin North Regional Director
Elsevier
/
View from the Top

Providing Resources to Improve Mexico's Scientific Production

Wed, 09/06/2017 - 14:32

Q: What solutions has Elsevier introduced to the Mexican scientific community? What are its main products?

A: We apply 140-plus years’ experience in simplifying and organizing life sciences information to ensure discoverability and accessibility of vital information. Elsevier’s solutions include Embase, which provides high-quality biomedical information with a level of comprehensiveness not seen anywhere else. It is recommended and trusted by the Cochrane Collaboration, international regulatory agencies and thousands of users across the pharmaceutical and medical devices industry. Even with the technological advances in genomics, only about 5 percent of drug candidates make it to market. Up to 30 percent of those that fail are due to inadequate or inaccurate target validation resulting in a lack of efficacy or unanticipated off-target effects, often leading to unforeseen serious adverse events. We offer a solution to mitigate this problem through our tool Pathway Studio. Providing global content from patents and 16,000 scientific journals, Elsevier’s Reaxys solution is designed to support the full range of chemistry research, including safety and toxicity analysis and method of analysis as well.

Q: What are the main research trends you have recognized in the pharmaceutical industry?

A: Big Pharma companies have demonstrated their interest in the available patient pool, which offers a substantial opportunity to accelerate their research. This has been considered a key factor for bringing clinical research to the country, although there is a concern from regulatory agencies and policymakers regarding the safety of patients. While both Big Pharma corporations and policymakers here in Mexico are still figuring out the most adequate formula of success, we see many clinical trial opportunities lost to other countries in the region. The challenge is not just the bureaucracy of policy but it is even at the infrastructure, personnel and information level.

There are so many generic molecules approved globally, but only handfuls make it into Mexican markets. Although already established as generic molecules globally, these advanced molecules are often considered “New Molecules” for registration purposes in Mexico. Also, we have seen bigger national companies take the lead in other areas of research, especially in identifying key generics for local manufacturing. The growing cost of APIs has always been a concern for local national pharmaceutical companies and on the other side the limited research output in terms of publications and patents is a concern for academic universities.

From an intellectual property standpoint of research, there are not many patents emerging, especially from the pharmaceutical sector. According to IMPI, local Mexican companies, government and academic institutes own an estimated 600 patents. This is approximately 2.5 times fewer than Brazil and approximately 100 times fewer than South Korea.

Q: How can Elsevier’s tools help boost productivity within Mexico’s healthcare services?

A: For any country in the current macroeconomic context there are three fundamental performance indicators for innovation and productivity: quality research output, intellectual property and application and socio-economic output. Elsevier has designed services and tools to improve and impact all three areas.

We have the privilege of working closely with almost 100 percent of international big corporations in the industry that clearly have adapted to the shift in the industry with respect to qualified information and analytics for their decision-making process from research to the commercial end. We also have witnessed how access to information has enabled global generics companies to evaluate and rationalize their portfolio and to strategically move away from their overdependence on top cash-cow molecules over of period of time. This shift is happening slowly but surely at top local Mexican pharmaceuticals. We are working closely with them to introduce and educate them on the current reliable resources through different programs and customized workshops.